Live Analyst Rating Changes 24429 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jared Haase
WB

Jared Haase

William Blair
Wall Street Analyst
★★★★☆
#608
on 13Foresight · ranked by our own returns
62%
Success Rate
+5.9%
Average Return
21 of 34 calls profitable · +3.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 62% of Jared Haase's ratings turned a profit when each position was held for 1 year — averaging +5.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

40 Buy 13 Hold 2 Sell
Jared's Stock Coverage 19 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AVAH
Aveanna Healthcare Holdings
 Aug 13, 2026 BUY Buy
-14.2% avg upside
18 analysts
 — +0.0% ·
DNA
Ginkgo Bioworks Holdings
 Aug 13, 2026 SELL Strong Sell
-2.6% avg upside
6 analysts
 — -0.0% ·
LFCR
Lifecore Biomedical
 Aug 11, 2026 BUY Strong Buy
+102.2% avg upside
10 analysts
 — -4.8% ·
CON
Concentra Group Holdings Parent, Inc.
 Aug 06, 2026 BUY Strong Buy
+10.3% avg upside
12 analysts
 — +15.0% ·
CRL
Charles River Labs
 Aug 05, 2026 BUY Strong Buy
-16.6% avg upside
35 analysts
 — +6.8% ·
EHC
Encompass Health
 Aug 05, 2026 BUY Strong Buy
-9.0% avg upside
22 analysts
 — +13.0% ·
CERT
Certara
 Aug 05, 2026 HOLD Buy
+61.3% avg upside
22 analysts
 — +0.6% ·
PNTG
Pennant Group
 Aug 05, 2026 BUY Strong Buy
-4.9% avg upside
9 analysts
 — -0.4% ·
USPH
US Physical Therapy
 Aug 05, 2026 HOLD Strong Buy
+11.3% avg upside
12 analysts
 — +2.9% ·
ADUS
Addus Homecare
 Aug 03, 2026 BUY Strong Buy
+8.8% avg upside
18 analysts
 — +0.2% ·
BTSG
BrightSpring Health Services, Inc.
 Jul 31, 2026 BUY Strong Buy
+9.4% avg upside
20 analysts
 — +2.4% ·
LH
Labcorp Holdings
 Jul 30, 2026 BUY Strong Buy
-15.9% avg upside
37 analysts
 — +2.2% ·
FTRE
Fortrea Holdings Inc.
 Jul 29, 2026 HOLD Buy
+17.5% avg upside
12 analysts
 — -6.9% ·
ICLR
Icon
 Jul 29, 2026 BUY Strong Buy
+12.5% avg upside
26 analysts
 — -7.8% ·
IQV
IQVIA Holdings
 Jul 28, 2026 BUY Strong Buy
+1.5% avg upside
39 analysts
 — -1.5% ·
MEDP
Medpace Holdings
 Jul 23, 2026 HOLD Buy
-16.9% avg upside
17 analysts
 — -4.5% ·
DGX
Quest Diagnostics
 Jul 23, 2026 BUY Buy
-22.3% avg upside
34 analysts
 — +4.3% ·
DH
Definitive Healthcare Corp
 Jul 02, 2026 HOLD Hold
+725.8% avg upside
19 analysts
 — -10.4% ·
INNV
InnovAge Holding
 May 05, 2026 HOLD Sell
-31.1% avg upside
12 analysts
 — +33.8% ·
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jared Haase — Frequently Asked Questions
How accurate are Jared Haase's stock ratings?
Based on the calls 13Foresight could measure, about 61% of Jared's ratings were profitable over a one-year hold, with an average return of +6.4% per rating, or +4.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jared ranked on 13Foresight?
Jared Haase is currently ranked #608 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jared cover?
Jared most recently has ratings on AVAH, DNA, LFCR, CON, CRL, EHC, CERT, PNTG, USPH, ADUS, BTSG, LH and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.